Series B

Biotech veteran Kamran Tavangar, who built a multi-billion dollar company at LabCentral, returns to lead its science strategy and shape the future of innovation.

A new partnership aims to move AI from costly experiments to real-world value in biopharma, combining specialized agents with strategic implementation.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

TwelveStone Health Partners and AI firm Tennr are teaming up to automate patient referrals, aiming to slash wait times and improve access to vital care.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

The junior explorer has raised crucial capital to advance its drilling programs in Quebec's prolific gold belt, signaling strong investor confidence.

The popular brunch chain is betting on a digital marketing guru to transform its customer experience and accelerate growth in a tech-driven market.

AI e-commerce firm Teikametrics hires Walmart Business co-founder Daryk Pengelly, signaling a major push for strategic growth and market dominance.

Facing soaring demand, AI robotics firm TechForce is seeking a global manufacturing partner, signaling a major shift from pilot programs to mass production.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

A South Korean AI firm is transforming Wall Street and the insurance industry with strategic funding from AWS and a unique human-centric technology.

New data reveals a stark split in private markets. Capital floods into infrastructure and AI, while concerns over PE exits and real estate persist.

SCALE AI's record funding fuels 44 new projects, aiming to accelerate homegrown AI and secure Canada's digital future amid fierce global competition.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

A new $50M fund says the old VC playbook is broken. We analyze if its AI-first model offers superior returns or is just a high-stakes bet on the future.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.